Pulse Biosciences reports Q3 net loss $18M, tightens focus on cardiac ablation, secures $65M loan from chairman

PULSE BIOSCIENCES, INC.

2022-Q3 EPS reported -$1.50 revenue$709,000

Q3 GAAP net loss $18.0M vs $14.3M in prior year; no revenue recorded.
Strategic pivot to cardiac cellular ablation for atrial fibrillation; dermatology business inventory reserve of $7.2M.
Entered $65M term loan at 5% interest, due March 2024, from Executive Chairman Robert Duggan.
Appointed Kevin Danahy as CEO, Darrin Uecker as CTO, and Robert Duggan as Executive Chairman.
Anticipates quarterly cash burn ~$8M from Q1 2023; cash $69.2M at Sep 30 vs $28.6M at Dec 31, 2021.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PULSE BIOSCIENCES, INC. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Pulse Biosciences, Inc. announced its financial results for the fiscal quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001625101-22-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.